Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure
Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders.
December S&P 500 futures (ESZ22) are trending lower -1.15% this morning, erasing yesterday’s gains after three major US benchmark indices bounced back sharply during the regular session as risk appetite...
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE)...
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better...